CLINICAL_TRIALS
trial_result
· 2022-01-28
Clinical Trial Update: A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage [Phase 3]
Summary
Phase 3 trial evaluating GB-0998 for unexplained recurrent miscarriage has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Japan Blood Products Organization | Conditions: Recurrent Miscarriage | Phase 3 | Status: COMPLETED